• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

隆突性皮肤纤维肉瘤的免疫组织化学特征及其在诊断和治疗中的实际应用

Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment.

作者信息

Haycox C L, Odland P B, Olbricht S M, Piepkorn M

机构信息

Division of Dermatology, University of Washington, Seattle 98195-6524, USA.

出版信息

J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):438-44. doi: 10.1016/s0190-9622(97)70146-4.

DOI:10.1016/s0190-9622(97)70146-4
PMID:9308560
Abstract

Dermatofibrosarcoma protuberans (DFSP) is a rare, clinically challenging, soft tissue tumor. The main histologic differential of DFSP is usually a dermatofibroma. In 1990, the first report appeared demonstrating that cells of DFSP express the human progenitor antigen CD34 on their surface. Since then, there have been increasing reports of the usefulness of immunohistochemical staining with CD34 to differentiate DFSP from dermatofibroma and other soft tissue tumors. This literature is reviewed with special emphasis on the insights studies have provided into the histogenesis of DFSP. The literature demonstrating the practical applications of CD34 staining in the diagnosis and treatment of DFSP is also discussed.

摘要

隆突性皮肤纤维肉瘤(DFSP)是一种罕见的、具有临床挑战性的软组织肿瘤。DFSP主要的组织学鉴别诊断通常是皮肤纤维瘤。1990年,首次有报告表明DFSP细胞在其表面表达人祖细胞抗原CD34。从那时起,越来越多的报告指出用CD34进行免疫组化染色有助于将DFSP与皮肤纤维瘤及其他软组织肿瘤区分开来。本文对该文献进行综述,特别强调了研究所提供的关于DFSP组织发生的见解。还讨论了证明CD34染色在DFSP诊断和治疗中的实际应用的文献。

相似文献

1
Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment.隆突性皮肤纤维肉瘤的免疫组织化学特征及其在诊断和治疗中的实际应用
J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):438-44. doi: 10.1016/s0190-9622(97)70146-4.
2
Dermatofibrosarcoma protuberans treated with Mohs surgery. A case with CD34 immunostaining variability.采用莫氏手术治疗隆突性皮肤纤维肉瘤。1例CD34免疫染色变异的病例。
Dermatol Surg. 1996 Feb;22(2):177-9. doi: 10.1111/j.1524-4725.1996.tb00503.x.
3
Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.HMGA1和HMGA2在皮肤纤维瘤和隆突性皮肤纤维肉瘤中的差异表达:潜在的诊断应用,以及与组织学结果、CD34和凝血因子XIIIa免疫反应性的比较
Am J Dermatopathol. 2004 Aug;26(4):267-72. doi: 10.1097/00000372-200408000-00001.
4
From Morphea to Dermatofibrosarcoma Protuberans.从硬斑病到隆突性皮肤纤维肉瘤。
Acta Dermatovenerol Croat. 2022 Sep;30(2):113-115.
5
Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa.腱生蛋白可将皮肤纤维瘤与隆突性皮肤纤维肉瘤区分开来:与CD34和因子ⅩⅢa的比较
Hum Pathol. 2001 Jan;32(1):50-6. doi: 10.1053/hupa.2001.21137.
6
Fibrosarcomatous ("high-grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance.纤维肉瘤样(“高级别”)隆突性皮肤纤维肉瘤:41例系列病例的临床病理及免疫组化研究,重点关注预后意义。
Am J Surg Pathol. 1998 May;22(5):576-87. doi: 10.1097/00000478-199805000-00009.
7
PRAME expression in fibrosarcomatous dermatofibrosarcoma protuberans.PRAME 在隆突性皮肤纤维肉瘤纤维肉瘤样变中的表达。
Sci Rep. 2024 Oct 3;14(1):22973. doi: 10.1038/s41598-024-74556-5.
8
A study of CD117 expression in dermatofibrosarcoma protuberans and cellular dermatofibroma.隆突性皮肤纤维肉瘤和细胞性皮肤纤维瘤中CD117表达的研究。
J Cutan Pathol. 2007 Nov;34(11):857-60. doi: 10.1111/j.1600-0560.2007.00731.x.
9
ALK-rearranged, CD34-positive spindle cell neoplasms resembling dermatofibrosarcoma protuberans: a study of seven cases.ALK 重排、CD34 阳性梭形细胞肿瘤,类似于隆突性皮肤纤维肉瘤:七例研究。
Histopathology. 2024 Oct;85(4):649-659. doi: 10.1111/his.15239. Epub 2024 Jun 13.
10
Bednar tumor (pigmented dermatofibrosarcoma protuberans) occurring in a site of prior immunization: immunochemical findings and therapy.发生于既往免疫接种部位的贝德纳瘤(色素性隆突性皮肤纤维肉瘤):免疫化学研究结果及治疗
J Am Acad Dermatol. 1999 Feb;40(2 Pt 2):315-7. doi: 10.1016/s0190-9622(99)70474-3.

引用本文的文献

1
Dermatofibrosarcoma Protuberans of Face: A Rare Entity and Review of Literature.面部隆突性皮肤纤维肉瘤:一种罕见病例及文献综述
Indian J Otolaryngol Head Neck Surg. 2022 Dec;74(Suppl 3):5469-5472. doi: 10.1007/s12070-021-02790-8. Epub 2021 Aug 3.
2
Cutaneous soft tissue sarcomas: survival-related factors.皮肤软组织肉瘤:生存相关因素。
Arch Dermatol Res. 2022 Sep;314(7):625-631. doi: 10.1007/s00403-021-02268-1. Epub 2021 Jul 17.
3
A hyperpigmented plaque in a female patient.一名女性患者身上的色素沉着斑。
JAAD Case Rep. 2020 Sep 30;6(12):1300-1302. doi: 10.1016/j.jdcr.2020.09.019. eCollection 2020 Dec.
4
Dermatofibrosarcoma Protuberans Mimicking Primary Breast Neoplasm: A case report and literature review.隆突性皮肤纤维肉瘤伪装原发性乳腺肿瘤:一例报告及文献复习
Sultan Qaboos Univ Med J. 2020 Aug;20(3):e368-e371. doi: 10.18295/squmj.2020.20.03.019. Epub 2020 Oct 5.
5
Unmasking dermatofibrosarcoma protuberans: Case report of an atypical presentation complicated by post-surgical excision.隐匿性隆突性皮肤纤维肉瘤:一例非典型表现并术后切除并发症的病例报告
Int J Surg Case Rep. 2020;69:101-104. doi: 10.1016/j.ijscr.2020.03.020. Epub 2020 Apr 3.
6
An unusual case of cauliflower-like tumor of breast.一例罕见的乳腺菜花状肿瘤病例。
Chin Med J (Engl). 2019 Nov 20;132(22):2767-2769. doi: 10.1097/CM9.0000000000000516.
7
Dermatofibrosarcoma protuberans: A rare and devastating tumor of the vulva.隆突性皮肤纤维肉瘤:一种罕见且侵袭性强的外阴肿瘤。
Gynecol Oncol Rep. 2019 Jan 25;28:9-11. doi: 10.1016/j.gore.2019.01.006. eCollection 2019 May.
8
A rare case of dermatofibrosarcoma protuberans of the forefoot.1例罕见的前足隆突性皮肤纤维肉瘤
Radiol Case Rep. 2016 Apr 4;11(2):102-5. doi: 10.1016/j.radcr.2016.02.013. eCollection 2016 Jun.
9
Dermatofibrosarcoma protuberans with pit-like lesions: A case report and literature review.伴有凹陷样病变的隆突性皮肤纤维肉瘤:一例报告及文献复习
Oncol Lett. 2015 Dec;10(6):3765-3768. doi: 10.3892/ol.2015.3741. Epub 2015 Sep 24.
10
Dermatofibrosarcoma Protuberans: A Rare Malignancy of the Breast.隆突性皮肤纤维肉瘤:一种罕见的乳腺恶性肿瘤。
Oman Med J. 2015 Sep;30(5):378-81. doi: 10.5001/omj.2015.75.